Home Stock

Stock Research: Jubilant Life Sciences

Independent stock analysis through peer comparison: Get the 360° View as an objective basis for stock decision-making and explore the detailed ranks.

Jubilant Life Sciences

NSI:JUBLPHARMA INE700A01033
10
  • Value
    68
  • Growth
    22
  • Safety
    Safety
    6
  • Combined
    6
  • Sentiment
    24
  • 360° View
    360° View
    10
Unlock
What factors are driving this 360° View?
Subscribe to View
Company Description

Jubilant Pharmova Limited is an India-based integrated pharmaceutical company. It operates in Radiopharma, Allergy Immunotherapy, Contract Development and Manufacturing Organisation-Sterile Injectables, Generics, Contract Research, Development and Manufacturing Organisation, and Proprietary Novel Drugs. The company operates in India. In the last fiscal year, the company had a market cap of $2201 million, profits of $575 million, and revenue of $847 million.

more

ANALYSIS: With an Obermatt 360° View of 10 (better than 10% compared with alternatives), overall professional sentiment and financial characteristics for the stock Jubilant Life Sciences are critical, mostly below average. The 360° View is based on consolidating four consolidated indicators, with three out of four indicators below average for Jubilant Life Sciences. Only the consolidated Value Rank has an attractive rank of 68, which means that the share price of Jubilant Life Sciences is on the lower side compared with the typical size in indicators such as revenues, profits, and invested capital. This means that the stock price is lower than for 68% of alternative stocks in the same industry. All other consolidated ranks are below average. The consolidated Growth Rank has a low rank of 22, which means that the company exhibits below-average growth momentum when looking at financial metrics such as revenue, profit, and invested capital growth as well as stock returns. The consolidated Safety Rank has a riskier rank of 6, meaning the company has a riskier financing structure than 94% comparable companies when looking at the amount of its debt, its refinancing requirements, and its ability to service debt. Finally, professionals are more pessimistic about the stock than for 76% of alternative investment opportunities, reflected in the consolidated Sentiment Rank of 24. ...read more

more
Strongest Rank Opinions Change
Weakest Rank Market Pulse
Country India
Industry Pharmaceuticals
Size Medium
Website jubl.com
Index
Jubilant Life Sciences stock price by TradingView. Not sourced by Obermatt.
Similar Add to Watchlist Similar See Similar Stocks
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 23-Jun-2026.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Value
Identifies how good a value the stock is.
Good Value Expensive
Combined
Consolidated view across Value, Growth, and Safety.
Good Tread Carefully
Growth
Shows a company's growth potential.
High Growth Tough Times
Sentiment
Shows what the market thinks of a stock.
Positive Sentiment Skepticism
Safety
Safety
Assesses how financially secure a company is.
Well-Financed High Leverage
360° View
360° View
Holistic stock analysis: all key non-/financial metrics
Good Watch Out

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
68 55 83 81
Growth
22 77 25 1
Safety
Safety
6 21 37 31
Sentiment
24 67 34 16
360° View
360° View
10 65 34 7
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Analyst Opinions
8 97 93 89
Opinions Change
3 50 50 50
Pro Holdings
n/a 60 21 4
Market Pulse
89 38 11 17
Sentiment
24 67 34 16
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
68 55 83 81
Growth
22 77 25 1
Safety Safety
6 21 37 31
Combined
6 49 45 13
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Price vs. Sales (P/S)
73 71 91 89
Price vs. Earnings (P/E)
46 36 69 89
Price vs. Book (P/B)
62 67 90 84
Dividend Yield
43 29 61 28
Value
68 55 83 81
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Revenue Growth
73 48 27 14
Profit Growth
21 98 8 6
Capital Growth
4 17 63 29
Stock Returns
33 99 65 7
Growth
22 77 25 1
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Leverage
22 16 22 22
Refinancing
26 66 90 88
Liquidity
28 18 16 22
Safety Safety
6 21 37 31

Similar Stocks

Discover high‑ranked alternatives to Jubilant Life Sciences and broaden your portfolio horizons.

Kalbe Farma

JKT:KLBF
Country: Indonesia
Industry: Pharmaceuticals
Size: Large
Full Stock Analysis

AIA Engineering

NSI:AIAENG
Country: India
Industry: Industrial Machinery
Size: Medium
Full Stock Analysis

Gujarat Gas

NSI:GUJGASLTD
Country: India
Industry: Gas Utilities
Size: Large
Full Stock Analysis

Aurobindo Pharma

NSI:AUROPHARMA
Country: India
Industry: Pharmaceuticals
Size: X-Large
Full Stock Analysis

Frequently Asked
Questions

The only strength is good value. All other factors (growth, safety, and sentiment) are below average. This stock is highly sensitive to a crisis and is not advisable. Avoid unless you have solid, independent reasons to believe a significant turnaround is imminent.

Obermatt provides unbiased stock analysis as a completely independent third party. We have no conflicts of interest with individual stock titles. Our data-driven analysis is based on algorithms honed over twelve years, giving you analysis that is free from personal bias and conflicts of interest.

The 360° View Rank indicates a company's overall performance across all major financial and non-financial metrics tracked by Obermatt. A 360° View Rank of 75 means the company is more well-rounded than 75% of similar companies. A high score indicates that the company is strong across the board; it is attractively priced, growing sustainably, financially stable, and well-regarded by the market. Learn more.

Become an Obermatt subscriber and see all of the similar stocks here.

OTHER FEATURES

Use the Platform to its Fullest

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.


30-day money back guarantee. Your subscription will renew until you cancel it, which you can do at any time.

What Our Customers Say

See how Obermatt improved their investing:

Review us See More Google Reviews